Work

AAV viral vectors as therapeutic interventions for inherited or non-inherited cardiac disorders: current aspects and future prospects

Year: 2025

Type: article

Abstract: Ischemic and non-ischemic cardiac diseases including arrhythmogenic cardiomyopathy and myocardial infarction, remain one of the leading causes of death worldwide despite significant advances in cardiovascular therapeutics. Current treatment strategies such as β-blockers, angiotensin-converting-enzyme inhibitors, and cardiac surgical interventions that include implantations of pacemakers and cardioverter-defibrillators are effective but often associated with serious side effects. In recent years, multiple cell-based therapies have emerged, aiming either to regeneration of myocardial or myofascial tissues or to correct defective gene using gene-transfer tools. Adeno-associated virus (AAVs), initially identified as contaminants of adeno-virus preparations, have since become one of the most important viral vectors for gene-transfer, especially in mammalian cells. This review analyzes and summarizes various AAV serotypes utilized in gene therapy programs for preclinical and clinical assays for cardiac disease.

Source: Frontiers in Medicine

DOI: 10.3389/fmed.2025.1678325

Authors: Vivek Kumar, Kalimuthu Kalishwaralal, Charu Chauhan, Gurpal Singh, Ravi Pratap Barnwal, Sachin Sharma

Institutions: University of Michigan, Bharati Vidyapeeth (Deemed to be University), Graphic Era University, Panjab University

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801